3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Melanoma
2
Interventions
pembrolizumab
74
Nivolumab
53
Ipilimumab
42
Cyclophosphamide
32
Interleukin-2
24
aldesleukin
23
Temozolomide
17
fludarabine
16
Biopsy
11
trametinib
10
fludarabine phosphate
10
dabrafenib
10
spartalizumab
8
Paclitaxel
8
Dacarbazine
8
sargramostim
7
cemiplimab
7
binimetinib
7
Cisplatin
7
Bevacizumab
7
poly ICLC
6
lenvatinib
6
epacadostat
6
Radiotherapy
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
montanide ISA 51
5
encorafenib
5
atezolizumab
5
Vemurafenib
5
Specimen Handling
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Melanoma
×
domatinostat
×
Clear all
NCT04133948
2025-03-10
DONIMI
The Netherlands Cancer Institute
Phase 1/2
Completed
44 enrolled
NCT03278665
2022-02-04
SENSITIZE
4SC AG
Phase 1/2
Completed
40 enrolled